{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Germ+Cell+Neoplasms&page=60",
    "query": {
      "condition": "Germ Cell Neoplasms",
      "page": 60
    },
    "page_size": 10
  },
  "pagination": {
    "page": 60,
    "page_size": 10,
    "total_count": 5243,
    "total_pages": 525,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Germ+Cell+Neoplasms&page=61&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Germ+Cell+Neoplasms&page=59&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-17T20:04:54.077Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01103635",
      "title": "Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Melanoma",
        "Stage IV Melanoma"
      ],
      "interventions": [
        {
          "name": "CD40 agonist monoclonal antibody CP-870,893",
          "type": "BIOLOGICAL"
        },
        {
          "name": "tremelimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Abramson Cancer Center at Penn Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2010-02",
      "completion_date": "2016-05-02",
      "has_results": false,
      "last_update_posted_date": "2020-04-07",
      "last_synced_at": "2026-11-17T20:04:54.077Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01103635"
    },
    {
      "nct_id": "NCT06176989",
      "title": "Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Chondrosarcoma",
        "Locally Advanced Chondrosarcoma",
        "Metastatic Sinonasal Adenocarcinoma",
        "Locally Advanced Sinonasal Adenocarcinoma",
        "Metastatic Large-cell Neuroendocrine Carcinoma",
        "Locally Advanced Large-cell Neuroendocrine Carcinoma",
        "Metastatic Olfactory Neuroblastoma",
        "Locally Advanced Olfactory Neuroblastoma",
        "Metastatic Sinonasal Undifferentiated Carcinoma",
        "Locally Advanced Sinonasal Undifferentiated Carcinoma"
      ],
      "interventions": [
        {
          "name": "Enasidenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 40,
      "start_date": "2024-03-04",
      "completion_date": "2030-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-11-05",
      "last_synced_at": "2026-11-17T20:04:54.077Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06176989"
    },
    {
      "nct_id": "NCT03535350",
      "title": "Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Ibrutinib",
          "type": "DRUG"
        },
        {
          "name": "Radiation",
          "type": "RADIATION"
        },
        {
          "name": "Temozolomide (TMZ)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2018-08-24",
      "completion_date": "2023-04-04",
      "has_results": false,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-11-17T20:04:54.077Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03535350"
    },
    {
      "nct_id": "NCT02388906",
      "title": "Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching Ipilimumab",
          "type": "OTHER"
        },
        {
          "name": "Placebo matching Nivolumab",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "15 Years and older"
      },
      "enrollment_count": 906,
      "start_date": "2015-03-16",
      "completion_date": "2024-10-16",
      "has_results": true,
      "last_update_posted_date": "2025-04-24",
      "last_synced_at": "2026-11-17T20:04:54.077Z",
      "location_count": 35,
      "location_summary": "Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 27 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02388906"
    },
    {
      "nct_id": "NCT03958006",
      "title": "Simultaneous Cochlear Implantation During Translabyrinthine Resection of Vestibular Schwannoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Vestibular Schwannoma",
        "Cochlear Implantation"
      ],
      "interventions": [
        {
          "name": "Cochlear implant",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Henry Ford Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 6,
      "start_date": "2018-12-05",
      "completion_date": "2023-01-30",
      "has_results": false,
      "last_update_posted_date": "2023-04-20",
      "last_synced_at": "2026-11-17T20:04:54.077Z",
      "location_count": 1,
      "location_summary": "Farmington Hills, Michigan",
      "locations": [
        {
          "city": "Farmington Hills",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03958006"
    },
    {
      "nct_id": "NCT02340884",
      "title": "A Pilot RCT of the PRISM Intervention for AYAs With Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cancer",
        "Acute Lymphoblastic Leukemia",
        "Lymphoma",
        "Sarcoma",
        "Acute Myelogenous Leukemia",
        "Brain Tumors",
        "Germ Cell Tumor"
      ],
      "interventions": [
        {
          "name": "Promoting Resilience In Stress Management (PRISM)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Seattle Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "13 Years to 25 Years"
      },
      "enrollment_count": 92,
      "start_date": "2015-01-30",
      "completion_date": "2021-12-19",
      "has_results": false,
      "last_update_posted_date": "2024-04-09",
      "last_synced_at": "2026-11-17T20:04:54.077Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02340884"
    },
    {
      "nct_id": "NCT04774952",
      "title": "Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "RMC-5552",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Revolution Medicines, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 58,
      "start_date": "2021-04-07",
      "completion_date": "2024-06-28",
      "has_results": false,
      "last_update_posted_date": "2025-04-15",
      "last_synced_at": "2026-11-17T20:04:54.077Z",
      "location_count": 8,
      "location_summary": "Irvine, California • Sacramento, California • San Francisco, California + 5 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04774952"
    },
    {
      "nct_id": "NCT07301268",
      "title": "GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma, IDH-Wildtype",
        "Progressive Astrocytoma, IDH-Mutant, Grade 4",
        "Progressive Glioblastoma",
        "Progressive Gliosarcoma",
        "Recurrent Astrocytoma, IDH-Mutant, Grade 4",
        "Recurrent Glioblastoma, IDH-Wildtype",
        "Recurrent Gliosarcoma",
        "Resectable Astrocytoma",
        "Resectable Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bispecific CD80-lgG4Fc-IL-2v Fusion Protein GI-102",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Multigated Acquisition Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Surgical Procedure",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2026-08-03",
      "completion_date": "2032-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-30",
      "last_synced_at": "2026-11-17T20:04:54.077Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07301268"
    },
    {
      "nct_id": "NCT00005968",
      "title": "Irofulven in Treating Patients With Stage IV Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma (Skin)"
      ],
      "interventions": [
        {
          "name": "irofulven",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "1999-11",
      "completion_date": "2002-12",
      "has_results": false,
      "last_update_posted_date": "2013-05-30",
      "last_synced_at": "2026-11-17T20:04:54.077Z",
      "location_count": 5,
      "location_summary": "Santa Monica, California • Denver, Colorado • Park Ridge, Illinois + 1 more",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Park Ridge",
          "state": "Illinois"
        },
        {
          "city": "Columbia",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005968"
    },
    {
      "nct_id": "NCT00991991",
      "title": "Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Melanoma (Skin)"
      ],
      "interventions": [
        {
          "name": "gene expression analysis",
          "type": "GENETIC"
        },
        {
          "name": "polymerase chain reaction",
          "type": "GENETIC"
        },
        {
          "name": "polymorphism analysis",
          "type": "GENETIC"
        },
        {
          "name": "matrix-assisted laser desorption/ionization time of flight mass spectrometry",
          "type": "OTHER"
        },
        {
          "name": "medical chart review",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "OTHER"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 5,
      "start_date": "2009-07",
      "completion_date": "2016-03",
      "has_results": false,
      "last_update_posted_date": "2016-05-17",
      "last_synced_at": "2026-11-17T20:04:54.077Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00991991"
    }
  ]
}